# AIM ImmunoTech Inc.: overview AIM · NYSE · CIK 946644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aim.md) · [Financials](/companies/aim/financials.md) · [Filings](/companies/aim/filings.md) · [Insiders](/companies/aim/insiders.md) Latest reported revenue: [$26.0k](/filings/0001493152-26-036609.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036609). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [35.0](/filings/0001493152-25-023894.md) | [45.0 d](/filings/0001493152-26-013301.md) | [16.0](/filings/0001493152-26-023750.md) | [25.0](/filings/0001493152-26-036609.md) | [26.0](/filings/0001493152-25-023894.md) | [21.0 d](/filings/0001493152-26-013301.md) | [22.0](/filings/0001493152-26-023750.md) | [26.0](/filings/0001493152-26-036609.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(12825.7%)](/filings/0001493152-25-023894.md) | [(13011.1%) d](/filings/0001493152-26-013301.md) | [(22618.8%)](/filings/0001493152-26-023750.md) | [(10584.0%)](/filings/0001493152-26-036609.md) | [(9411.5%)](/filings/0001493152-25-023894.md) | [(14057.1%) d](/filings/0001493152-26-013301.md) | [(10118.2%)](/filings/0001493152-26-023750.md) | [(13511.5%)](/filings/0001493152-26-036609.md) | | Net margin | % | [(10571.4%)](/filings/0001493152-25-023894.md) | [(13260.0%) d](/filings/0001493152-26-013301.md) | [(23156.3%)](/filings/0001493152-26-036609.md) | [(11176.0%)](/filings/0001493152-26-036609.md) | [(12630.8%)](/filings/0001493152-25-023894.md) | [(19881.0%) d](/filings/0001493152-26-013301.md) | [(13740.9%)](/filings/0001493152-26-036609.md) | [(14569.2%)](/filings/0001493152-26-036609.md) | | Diluted EPS | $ per share | [(6.00)](/filings/0001493152-25-023894.md) | not reported | [(0.05)](/filings/0001493152-26-023750.md) | [(3.68)](/filings/0001493152-26-036609.md) | [1.57](/filings/0001493152-25-023894.md) | not reported | [(0.69)](/filings/0001493152-26-023750.md) | [(0.43)](/filings/0001493152-26-036609.md) | | Free cash flow | $k | not reported | [(3,955) d](/filings/0001493152-26-013301.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001493152-23-010351.md) | [0.1](/filings/0001493152-24-012058.md) | [0.2](/filings/0001641172-25-000847.md) | [0.2](/filings/0001493152-26-013301.md) | [0.1](/filings/0001493152-26-013301.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(13954.1%)](/filings/0001493152-23-010351.md) | [(14129.8%)](/filings/0001493152-24-012058.md) | [(15800.0%)](/filings/0001641172-25-000847.md) | [(11630.6%)](/filings/0001493152-26-013301.md) | [(13254.5%)](/filings/0001493152-26-013301.md) | | Net margin | % | [(14168.1%)](/filings/0001493152-23-010351.md) | [(13790.8%)](/filings/0001493152-24-012058.md) | [(14337.6%)](/filings/0001641172-25-000847.md) | [(10188.2%)](/filings/0001493152-26-013301.md) | [(15861.4%)](/filings/0001493152-26-013301.md) | | Diluted EPS | $ per share | [(0.40)](/filings/0001493152-22-008324.md) | [(0.40)](/filings/0001493152-24-012058.md) | [(0.60)](/filings/0001641172-25-000847.md) | [(30.92)](/filings/0001493152-26-013301.md) | [(8.62)](/filings/0001493152-26-013301.md) | | Free cash flow | $m | [(14.0)](/filings/0001493152-23-010351.md) | [(16.2)](/filings/0001493152-24-012058.md) | not reported | [(14.9)](/filings/0001493152-26-013301.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aim/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $229.4k | 807,885 | | Added +787,838 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $14.4k | 50,864 | | Added +50,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.1k | 46,003 | | Added +16,085 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $9.2k | 32,444 | | New +32,444 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $8.2k | 28,931 | | Added +28,930 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $6.2k | 21,859 | | New +21,859 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $5.0k | 17,519 | | Unchanged | | [Ground Swell Capital, LLC](/funds/1534450.md) | 2026-06-30 | $3.5k | 12,222 | | New +12,222 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.3k | 4,668 | | Unchanged | | [Continuum Advisory, LLC](/funds/1846532.md) | 2026-06-30 | $142 | 500 | | New +500 | ## Recent filings [All 1,223 filings](/companies/aim/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 16:05 ET | [DEF 14A](/filings/0001493152-26-045102.md) | Proxy statement, period 2026-09-30 | 0001493152-26-045102 | | 2026-09-14 | 16:35 ET | [8-K](/filings/0001493152-26-042592.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-042592 | | 2026-09-10 | 16:35 ET | [8-K](/filings/0001493152-26-042196.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-042196 | | 2026-09-04 | 16:05 ET | [8-K](/filings/0001493152-26-041537.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-041537 | | 2026-08-11 | 08:40 ET | [8-K](/filings/0001493152-26-036996.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036996 | | 2026-08-10 | 08:40 ET | [8-K](/filings/0001493152-26-036753.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-036753 | | 2026-08-07 | 16:35 ET | [10-Q](/filings/0001493152-26-036609.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036609 | | 2026-08-06 | 17:22 ET | [8-K](/filings/0001493152-26-036408.md) | 1.01 Entry into a material agreement; 5.08 Item not in the standard list; 9.01 Financial statements and exhibits | 0001493152-26-036408 | | 2026-08-05 | 08:00 ET | [8-K](/filings/0001493152-26-036104.md) | 1.02 Termination of a material agreement | 0001493152-26-036104 | | 2026-07-16 | 16:05 ET | [8-K](/filings/0001493152-26-033514.md) | 5.07 Shareholder vote results | 0001493152-26-033514 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013301.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a8d7b423-2abf-4b95-b402-26ee4e684078) ## About the filer - CIK: 946644 - Tickers: AIM - Exchange: NYSE - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 12:13 ET. No prices; not investment advice.